Genagon Therapeutics drug development is based on ground-breaking discoveries of unstudied proteins and their life cycles in innate immune cells. Genagon was founded in 2015 and is growing a strong and broad patent portfolio with opportunities for internal development and future partnerships. The company is supported financially by among others, Beijer Ventures and Almi Invest.